| |
著者: Jong Wook Lee
雑誌名: Int J Hematol. 2008 Jul;88(1):16-23. doi: 10.1007/s12185-008-0117-0. Epub 2008 Jul 5.
Abstract/Text
Emerging clinical data indicate that transfusion-dependent patients with bone marrow-failure syndromes (BMFS) are at risk of the consequences of iron overload, including progressive damage to hepatic, endocrine, and cardiac organs. Despite the availability of deferoxamine (DFO) in Korea since 1998, data from patients with myelodysplastic syndromes, aplastic anemia, and other BMFS show significant iron overload and damage to the heart and liver. The recent introduction of deferasirox, a once-daily, oral iron chelator, may improve the availability of iron chelation therapy to iron-overloaded patients, and improve compliance in patients who may otherwise find adherence to the DFO regimen difficult.
PMID 18604581 Int J Hematol. 2008 Jul;88(1):16-23. doi: 10.1007/s12185-008-0117-0. Epub 2008 Jul 5.
|
